Clinical outcome and predicted NK alloreactivity
| . | All, no. (%) . | NK alloreactivity, no. (%) . | No NK alloreactivity, no. (%) . | P . |
|---|---|---|---|---|
| All patients | 56 | 27 | 29 | |
| Graft rejection | 6 (10.7) | 2 (7.4) | 4 (13.8) | .73 |
| Death before engraftment | 7 (12.5) | 2 (7.4) | 5 (17.2) | .48 |
| Informative patients for engraftment | 43 | 23 | 20 | |
| Disease relapse | 13 (30.2) | 8 (34.8) | 5 (25) | .77* |
| Transplant-related mortality | 17 (39.5) | 9 (39.1) | 8 (40) | .94* |
| aGvHD | 11 (25.6) | 8 (34.8) | 3 (15) | .18 |
| Overall grade I | 2 (4.6) | 1 (4.3) | 1 (5) | |
| Overall grade II | 7 (16.3) | 5 (21.7) | 2 (10) | |
| Overall grade III | 2 (4.6) | 2 (8.7) | 0 | |
| Overall grade IV | 0 | 0 | 0 | |
| T-cell reconstitution at day 120 after HSCT† | 20 (46.5) | 10 (43.5) | 10 (50) | .94 |
| . | All, no. (%) . | NK alloreactivity, no. (%) . | No NK alloreactivity, no. (%) . | P . |
|---|---|---|---|---|
| All patients | 56 | 27 | 29 | |
| Graft rejection | 6 (10.7) | 2 (7.4) | 4 (13.8) | .73 |
| Death before engraftment | 7 (12.5) | 2 (7.4) | 5 (17.2) | .48 |
| Informative patients for engraftment | 43 | 23 | 20 | |
| Disease relapse | 13 (30.2) | 8 (34.8) | 5 (25) | .77* |
| Transplant-related mortality | 17 (39.5) | 9 (39.1) | 8 (40) | .94* |
| aGvHD | 11 (25.6) | 8 (34.8) | 3 (15) | .18 |
| Overall grade I | 2 (4.6) | 1 (4.3) | 1 (5) | |
| Overall grade II | 7 (16.3) | 5 (21.7) | 2 (10) | |
| Overall grade III | 2 (4.6) | 2 (8.7) | 0 | |
| Overall grade IV | 0 | 0 | 0 | |
| T-cell reconstitution at day 120 after HSCT† | 20 (46.5) | 10 (43.5) | 10 (50) | .94 |